Tag: AHA 2024
AHA 2024: Three trials shed new light on AF ablation outcomes
Late-breaking results from the PROMPT-AF, CRRF-PeAF and ARREST-AF trials were presented recently at the American Heart Association (AHA) Scientific Sessions (16–18 November 2024, Chicago, USA),...
AHA 2024: Lifestyle and risk-factor changes improve AF symptoms—not burden—compared to...
Treatment with the Type 2 diabetes medication metformin, lifestyle changes, or a combination of both, did not improve atrial fibrillation (AF) burden or progression...
AHA 2024: Five-year Amulet IDE data show similar outcomes with Amplatzer...
Latest data from the Amulet investigational device exemption (IDE) trial, comparing the Amplatzer Amulet (Abbott) left atrial appendage occluder (LAAO) to the first-generation Watchman...
AHA 2024: Blood thinners fail to reduce cognitive decline in younger...
Prescribing anticoagulation medications to adults younger than 65 years of age who have atrial fibrillation (AF) but no other risk factors for stroke does not...
AHA 2024: OPTION trial reports positive outcomes for Watchman FLX at...
Three-year results from the OPTION clinical trial, comparing the Watchman FLX (Boston Scientific) left atrial appendage closure (LAAC) system to oral anticoagulation for stroke...
AHA 2024: Ablation potentially superior to medication for post-heart attack VT
Ablation may be a better first-line treatment for heart attack survivors experiencing dangerous episodes of ventricular tachycardia (VT), according to late-breaking science presented recently...
AHA 2024: Reconditioned pacemakers appear to perform as well as new...
A randomised trial comparing previously used and new pacemakers in patients with heart rhythm disorders has found reconditioned devices to be as safe and...
Study indicates more exercise is better—but even moderate amounts may reduce...
An extra hour of physical activity every week may lower a person’s chance of developing the most common type of arrythmia by 11%, a...